Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Multiple Sclerosis

Free Subscription Articles published in J Neurol Retrieve available abstracts of 288 articles: HTML format

Single Articles

April 2024
1. SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
   Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
   J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
   PubMed     Abstract available
   
   
   
2. HIRT J, Dembowska K, Woelfle T, Axfors C, et al
   Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
   J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
   PubMed     Abstract available
   
   
   
3. SINGER BA, Feng J, Chiong-Rivero H
   Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
   J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
   PubMed     Abstract available
   
   
   
4. STALTER J, Pars K, Witt K
   Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
   J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
   PubMed     Abstract available
   
   
   
5. CELIK M, Baba C, Irmak C, Ozakbas S, et al
   Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
   J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
   PubMed     Abstract available
   
   
   
6. STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
   Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
   J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
   PubMed     Abstract available
   
   
   
7. MAIDA E, Moccia M, Palladino R, Borriello G, et al
   ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
   J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
   PubMed     Abstract available
   
   
   
8. SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
   Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
   J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
   PubMed     Abstract available
   
   
   
9. GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
   Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
   J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
   PubMed    
   
   
   
10. TEDONE N, Vizzino C, Meani A, Gallo A, et al
    The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
    J Neurol. 2024;271:1813-1823.
    PubMed     Abstract available
    
    
    
11. GLASER A, Butzkueven H, van der Walt A, Gray O, et al
    Big Multiple Sclerosis Data network: an international registry research network.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
    PubMed     Abstract available
    
    
    
12. HUA T, Fan H, Duan Y, Tian D, et al
    Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
    PubMed     Abstract available
    
    
    March 2024
13. GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
    Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
    J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
    PubMed     Abstract available
    
    
    
14. SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
    Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
    PubMed     Abstract available
    
    
    
15. MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
    Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
    PubMed     Abstract available
    
    
    
16. PILOTTO S, Floris M, Solla P, Pugliatti M, et al
    Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
    PubMed     Abstract available
    
    
    
17. GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
    Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
    J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
    PubMed     Abstract available
    
    
    
18. ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
    Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
    J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
    PubMed     Abstract available
    
    
    
19. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
    J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
    PubMed    
    
    
    
20. KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
    The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
    PubMed     Abstract available
    
    
    
21. HEGEN H, Berek K, Deisenhammer F, Berger T, et al
    Sex impacts treatment decisions in multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
    PubMed     Abstract available
    
    
    
22. HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
    Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
    PubMed     Abstract available
    
    
    
23. ZID Y, Robertson NP
    Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
    J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
    PubMed    
    
    
    
24. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
    PubMed     Abstract available
    
    
    February 2024
25. SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
    Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
    J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
    PubMed     Abstract available
    
    
    
26. TOLJAN K, Briggs FBS
    Male sexual and reproductive health in multiple sclerosis: a scoping review.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
    PubMed     Abstract available
    
    
    
27. LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
    A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
    PubMed     Abstract available
    
    
    
28. VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
    Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
    J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
    PubMed     Abstract available
    
    
    
29. CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
    Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
    PubMed    
    
    
    
30. BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
    The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
    J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
    PubMed     Abstract available
    
    
    
31. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
    Prodromal multiple sclerosis: considerations and future utility.
    J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
    PubMed     Abstract available
    
    
    January 2024
32. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
    Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
    PubMed     Abstract available
    
    
    
33. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
    Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
    PubMed     Abstract available
    
    
    
34. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
    Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
    J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
    PubMed     Abstract available
    
    
    
35. FENG G, Posa S, Sureshkumar A, Simpson S, et al
    Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
    J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
    PubMed     Abstract available
    
    
    
36. ZHENG P, Sandroff BM, Motl RW
    Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
    J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
    PubMed     Abstract available
    
    
    
37. TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
    Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
    J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
    PubMed     Abstract available
    
    
    
38. LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
    Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
    J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
    PubMed     Abstract available
    
    
    
39. MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
    Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
    J Neurol. 2024;271:374-385.
    PubMed     Abstract available
    
    
    December 2023
40. AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
    Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
    J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
    PubMed    
    
    
    
41. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
    PubMed     Abstract available
    
    
    
42. ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
    Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
    PubMed     Abstract available
    
    
    
43. MISTRI D, Valsasina P, Storelli L, Filippi M, et al
    Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
    PubMed     Abstract available
    
    
    
44. HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
    Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
    J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
    PubMed     Abstract available
    
    
    
45. COVEY TJ, Golan D, Sergott R, Wilken J, et al
    Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
    J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
    PubMed     Abstract available
    
    
    
46. ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
    Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
    PubMed     Abstract available
    
    
    
47. TSAI CC, Jette S, Tremlett H
    Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
    J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
    PubMed     Abstract available
    
    
    
48. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
    J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
    PubMed     Abstract available
    
    
    November 2023
49. MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
    Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
    PubMed     Abstract available
    
    
    
50. MISTRI D, Tedone N, Biondi D, Vizzino C, et al
    Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
    J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
    PubMed     Abstract available
    
    
    
51. JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
    Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
    PubMed     Abstract available
    
    
    
52. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
    COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
    PubMed     Abstract available
    
    
    
53. KENNEDY PGE, George W, Yu X
    The elusive nature of the oligoclonal bands in multiple sclerosis.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
    PubMed     Abstract available
    
    
    
54. DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
    SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
    J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
    PubMed     Abstract available
    
    
    
55. FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
    Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
    J Neurol. 2023;270:5392-5397.
    PubMed     Abstract available
    
    
    
56. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
    Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
    J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
    PubMed    
    
    
    October 2023
57. MANTERO V, Cordano C, Balgera R, Basilico P, et al
    Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
    PubMed    
    
    
    
58. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
    Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
    PubMed     Abstract available
    
    
    
59. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
    Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
    PubMed     Abstract available
    
    
    
60. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
    Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
    J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
    PubMed     Abstract available
    
    
    
61. ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
    Identification and management of subclinical disease activity in early multiple sclerosis: a review.
    J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
    PubMed     Abstract available
    
    
    
62. ZINGANELL A, Gobel G, Berek K, Hofer B, et al
    Multiple sclerosis in the elderly: a retrospective cohort study.
    J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
    PubMed     Abstract available
    
    
    
63. SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
    Multiple sclerosis: time for early treatment with high-efficacy drugs.
    J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
    PubMed     Abstract available
    
    
    
64. RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
    Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
    PubMed     Abstract available
    
    
    September 2023
65. RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
    Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
    PubMed     Abstract available
    
    
    
66. LI Y, Saul A, Taylor B, Ponsonby AL, et al
    Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
    J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
    PubMed     Abstract available
    
    
    
67. WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
    Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
    PubMed     Abstract available
    
    
    
68. FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
    Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
    J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
    PubMed     Abstract available
    
    
    
69. MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
    Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
    J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
    PubMed    
    
    
    
70. JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
    Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
    J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
    PubMed     Abstract available
    
    
    August 2023
71. FERRAND M, Epstein J, Soudant M, Guillemin F, et al
    Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.
    J Neurol. 2023 Aug 31. doi: 10.1007/s00415-023-11905.
    PubMed     Abstract available
    
    
    
72. BONACCHI R, Valsasina P, Pagani E, Meani A, et al
    Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
    PubMed     Abstract available
    
    
    
73. TOSCANO S, Chisari CG, Lo Fermo S, Gulino G, et al
    A dynamic interpretation of kappaFLC index for the diagnosis of multiple sclerosis: a change of perspective.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11952.
    PubMed     Abstract available
    
    
    
74. JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
    Cortical thickness and cognition in older people with multiple sclerosis.
    J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
    PubMed     Abstract available
    
    
    
75. SPIERER R, Lavi I, Bloch S, Mazar M, et al
    Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
    J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11935.
    PubMed     Abstract available
    
    
    
76. KLETENIK I, Cohen AL, Glanz BI, Ferguson MA, et al
    Multiple sclerosis lesions that impair memory map to a connected memory circuit.
    J Neurol. 2023 Aug 2. doi: 10.1007/s00415-023-11907.
    PubMed     Abstract available
    
    
    July 2023
77. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Correction to: Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jul 26. doi: 10.1007/s00415-023-11874.
    PubMed    
    
    
    
78. NOTEBOOM S, van Nederpelt DR, Bajrami A, Moraal B, et al
    Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.
    J Neurol. 2023 Jul 19. doi: 10.1007/s00415-023-11870.
    PubMed     Abstract available
    
    
    
79. ROCCA MA, Valsasina P, Lamanna MT, Colombo B, et al
    Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
    J Neurol. 2023 Jul 18. doi: 10.1007/s00415-023-11858.
    PubMed     Abstract available
    
    
    
80. LOMBARDO-DEL TORO P, Bragado-Trigo I, Arroyo P, Tena-Cucala R, et al
    Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.
    J Neurol. 2023 Jul 17. doi: 10.1007/s00415-023-11865.
    PubMed    
    
    
    
81. PETROU P, Achiron A, Cohen EG, Garty M, et al
    Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint.
    J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
    PubMed     Abstract available
    
    
    
82. AMATO MP, Bergamaschi R, Centonze D, Mirabella M, et al
    Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
    J Neurol. 2023 Jul 5. doi: 10.1007/s00415-023-11820.
    PubMed     Abstract available
    
    
    
83. NICULAE AS, Niculae LE, Vacaras C, Vacaras V, et al
    Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jul 2. doi: 10.1007/s00415-023-11841.
    PubMed     Abstract available
    
    
    
84. JARIUS S, Aktas O, Ayzenberg I, Bellmann-Strobl J, et al
    Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    J Neurol. 2023;270:3341-3368.
    PubMed     Abstract available
    
    
    June 2023
85. RUGGIERI S, Prosperini L, Petracca M, Logoteta A, et al
    The added value of spinal cord lesions to disability accrual in multiple sclerosis.
    J Neurol. 2023 Jun 29. doi: 10.1007/s00415-023-11829.
    PubMed     Abstract available
    
    
    
86. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jun 21. doi: 10.1007/s00415-023-11806.
    PubMed     Abstract available
    
    
    
87. ROSENSTEIN I, Axelsson M, Novakova L, Malmestrom C, et al
    Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Jun 14. doi: 10.1007/s00415-023-11817.
    PubMed     Abstract available
    
    
    
88. GRANGE E, Solaro C, Di Giovanni R, Marengo D, et al
    The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11801.
    PubMed     Abstract available
    
    
    
89. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Jun 5. doi: 10.1007/s00415-023-11784.
    PubMed    
    
    
    
90. HOLTZER R, Choi J, Motl RW, Foley FW, et al
    Individual reserve in aging and neurological disease.
    J Neurol. 2023;270:3179-3191.
    PubMed     Abstract available
    
    
    May 2023
91. LOUAPRE C, Rosenzwajg M, Golse M, Roux A, et al
    A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 May 28. doi: 10.1007/s00415-023-11690.
    PubMed     Abstract available
    
    
    
92. AZZIMONTI M, Preziosa P, Pagani E, Valsasina P, et al
    Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
    J Neurol. 2023 May 18. doi: 10.1007/s00415-023-11778.
    PubMed     Abstract available
    
    
    
93. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11772.
    PubMed    
    
    
    
94. MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
    Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
    J Neurol. 2023;270:2559-2566.
    PubMed     Abstract available
    
    
    April 2023
95. KREMMYDA O, Feil K, Bardins S, Strupp M, et al
    Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11730.
    PubMed    
    
    
    
96. VAN DAM M, de Jong BA, Willemse EAJ, Nauta IM, et al
    A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11676.
    PubMed     Abstract available
    
    
    
97. MARGONI M, Pagani E, Preziosa P, Gueye M, et al
    Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
    J Neurol. 2023 Apr 24. doi: 10.1007/s00415-023-11736.
    PubMed     Abstract available
    
    
    
98. KOUTSOURAKI E, Theodoros K, Eleni G, Marianna K, et al
    Autonomic nervous system disorders in multiple sclerosis.
    J Neurol. 2023 Apr 21. doi: 10.1007/s00415-023-11725.
    PubMed     Abstract available
    
    
    
99. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Apr 19. doi: 10.1007/s00415-023-11686.
    PubMed     Abstract available
    
    
    
100. GANAPATHY SUBRAMANIAN R, Zivadinov R, Bergsland N, Dwyer MG, et al
     Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis.
     J Neurol. 2023 Apr 17. doi: 10.1007/s00415-023-11709.
     PubMed     Abstract available
     
     
     
101. YEO T, Siew RWE, Gulam MY, Tye JSN, et al
     COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
     J Neurol. 2023 Apr 7:1-9. doi: 10.1007/s00415-023-11692.
     PubMed     Abstract available
     
     
     
102. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
     Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
     J Neurol. 2023 Apr 7:1-12. doi: 10.1007/s00415-023-11700.
     PubMed     Abstract available
     
     
     
103. VRENKEN H, Battaglini M, de Vos ML, Nagtegaal GJ, et al
     Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon beta-1a.
     J Neurol. 2023;270:2271-2282.
     PubMed     Abstract available
     
     
     
104. LEHTO J, Sucksdorff M, Nylund M, Raitanen R, et al
     PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
     J Neurol. 2023;270:2329-2332.
     PubMed     Abstract available
     
     
     
105. ASTBURY L, Kalra S, Tanasescu R, Constantinescu CS, et al
     CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
     J Neurol. 2023;270:2042-2047.
     PubMed     Abstract available
     
     
     March 2023
106. PLESS S, Woelfle T, Naegelin Y, Lorscheider J, et al
     Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
     J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11671.
     PubMed     Abstract available
     
     
     
107. TORRES P, Sancho-Saldana A, Gil Sanchez A, Peralta S, et al
     A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
     J Neurol. 2023 Mar 18:1-12. doi: 10.1007/s00415-023-11575.
     PubMed     Abstract available
     
     
     
108. ROMANO F, Motl RW, Valsasina P, Amato MP, et al
     Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis.
     J Neurol. 2023 Mar 18. doi: 10.1007/s00415-023-11664.
     PubMed     Abstract available
     
     
     
109. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
     Correction to: Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
     J Neurol. 2023 Mar 13. doi: 10.1007/s00415-023-11646.
     PubMed    
     
     
     
110. MOGAVERO MP, Lanza G, Bruni O, DelRosso LM, et al
     Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.
     J Neurol. 2023 Mar 11. doi: 10.1007/s00415-023-11655.
     PubMed     Abstract available
     
     
     
111. VELDKAMP R, D'hooge M, Sandroff BM, DeLuca J, et al
     Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
     J Neurol. 2023 Mar 7. doi: 10.1007/s00415-023-11636.
     PubMed     Abstract available
     
     
     
112. LI G, You Q, Hou X, Zhang S, et al
     The effect of exercise on cognitive function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
     J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11649.
     PubMed     Abstract available
     
     
     
113. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
     Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
     J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11644.
     PubMed     Abstract available
     
     
     
114. BARLETTA VT, Herranz E, Treaba CA, Mehndiratta A, et al
     In vivo characterization of microglia and myelin relation in multiple sclerosis by combined (11)C-PBR28 PET and synthetic MRI.
     J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11621.
     PubMed     Abstract available
     
     
     
115. DIETMANN AS, Kruse N, Stork L, Gloth M, et al
     Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
     J Neurol. 2023;270:1416-1429.
     PubMed     Abstract available
     
     
     February 2023
116. BAETGE SJ, Filser M, Renner A, Raithel LM, et al
     Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms.
     J Neurol. 2023 Feb 25:1-14. doi: 10.1007/s00415-023-11616.
     PubMed     Abstract available
     
     
     
117. MONTINI F, Nozzolillo A, Rancoita PMV, Zanetta C, et al
     Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
     J Neurol. 2023 Feb 16:1-8. doi: 10.1007/s00415-023-11618.
     PubMed     Abstract available
     
     
     
118. SWINNEN S, De Wit D, Van Cleemput L, Cassiman C, et al
     Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review.
     J Neurol. 2023;270:1178-1186.
     PubMed     Abstract available
     
     
     
119. HUANG L, Wang Y, Zhang R
     Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
     J Neurol. 2023;270:759-768.
     PubMed     Abstract available
     
     
     
120. GERNERT JA, Wicklein R, Hemmer B, Kumpfel T, et al
     Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).
     J Neurol. 2023;270:1135-1140.
     PubMed     Abstract available
     
     
     
121. MAGRO G, Barone S, Tosto F, De Martino A, et al
     Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.
     J Neurol. 2023;270:595-600.
     PubMed     Abstract available
     
     
     January 2023
122. CAGOL A, Fuertes NC, Stoessel M, Barakovic M, et al
     Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
     J Neurol. 2023 Jan 10. doi: 10.1007/s00415-022-11535.
     PubMed     Abstract available
     
     
     
123. DAVION JB, Jougleux C, Lopes R, Leclerc X, et al
     Relation between retina, cognition and brain volumes in MS: a consequence of asymptomatic optic nerve lesions.
     J Neurol. 2023;270:240-249.
     PubMed     Abstract available
     
     
     December 2022
124. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
     Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
     J Neurol. 2022 Dec 27. doi: 10.1007/s00415-022-11540.
     PubMed    
     
     
     
125. LOONSTRA FC, Falize KF, de Ruiter LRJ, Schoonheim MM, et al
     Adipokines in multiple sclerosis patients are related to clinical and radiological measures.
     J Neurol. 2022 Dec 23. doi: 10.1007/s00415-022-11519.
     PubMed     Abstract available
     
     
     
126. SEN MK, Hossain MJ, Mahns DA, Brew BJ, et al
     Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.
     J Neurol. 2022 Dec 15. doi: 10.1007/s00415-022-11507.
     PubMed     Abstract available
     
     
     
127. ALBERGONI M, Storelli L, Preziosa P, Rocca MA, et al
     The insula modulates the effects of aerobic training on cardiovascular function and ambulation in multiple sclerosis.
     J Neurol. 2022 Dec 12:1-10. doi: 10.1007/s00415-022-11513.
     PubMed     Abstract available
     
     
     
128. GANZETTI M, Graves JS, Holm SP, Dondelinger F, et al
     Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.
     J Neurol. 2022 Dec 5. doi: 10.1007/s00415-022-11494.
     PubMed     Abstract available
     
     
     
129. MOCCIA M, Affinito G, Berera G, Marrazzo G, et al
     Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
     J Neurol. 2022;269:6504-6511.
     PubMed     Abstract available
     
     
     
130. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
     Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.
     J Neurol. 2022;269:6366-6376.
     PubMed     Abstract available
     
     
     November 2022
131. SIMPSON R, Posa S, Bruno T, Simpson S, et al
     Conceptualization, use, and outcomes associated with compassion in the care of people with multiple sclerosis: a scoping review.
     J Neurol. 2022 Nov 29. doi: 10.1007/s00415-022-11497.
     PubMed     Abstract available
     
     
     
132. PREZIOSA P, Rocca MA, Pagani E, Valsasina P, et al
     Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis.
     J Neurol. 2022 Nov 27. doi: 10.1007/s00415-022-11486.
     PubMed     Abstract available
     
     
     
133. FILIPPI M, Preziosa P, Arnold DL, Barkhof F, et al
     Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.
     J Neurol. 2022 Nov 24. doi: 10.1007/s00415-022-11488.
     PubMed     Abstract available
     
     
     
134. MIRMOSAYYEB O, Zivadinov R, Weinstock-Guttman B, Benedict RHB, et al
     Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis.
     J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11449.
     PubMed     Abstract available
     
     
     
135. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
     Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
     J Neurol. 2022 Nov 14. pii: 10.1007/s00415-022-11405.
     PubMed     Abstract available
     
     
     
136. GALPERIN I, Mirelman A, Schmitz-Hubsch T, Hsieh KL, et al
     Treadmill training with virtual reality to enhance gait and cognitive function among people with multiple sclerosis: a randomized controlled trial.
     J Neurol. 2022 Nov 11. pii: 10.1007/s00415-022-11469.
     PubMed     Abstract available
     
     
     
137. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
     Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
     J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11479.
     PubMed     Abstract available
     
     
     
138. SIMPSON R, Posa S, Langer L, Bruno T, et al
     A systematic review and meta-analysis exploring the efficacy of mindfulness-based interventions on quality of life in people with multiple sclerosis.
     J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11451.
     PubMed     Abstract available
     
     
     
139. NIINO M, Fukumoto S, Okuno T, Sanjo N, et al
     Health-related quality of life in Japanese patients with multiple sclerosis.
     J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11453.
     PubMed     Abstract available
     
     
     
140. KURI A, Vickaryous N, Awad A, Jacobs BM, et al
     Vitamin D genetic risk scores in multiple sclerosis.
     J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11466.
     PubMed     Abstract available
     
     
     October 2022
141. OMARY R, Bockisch CJ, De Vere-Tyndall A, Pazahr S, et al
     Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis.
     J Neurol. 2022 Oct 31. pii: 10.1007/s00415-022-11428.
     PubMed     Abstract available
     
     
     
142. WUSCHEK A, Bussas M, El Husseini M, Harabacz L, et al
     Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis.
     J Neurol. 2022 Oct 7. pii: 10.1007/s00415-022-11407.
     PubMed     Abstract available
     
     
     
143. PREZIOSA P, Pagani E, Meani A, Marchesi O, et al
     NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.
     J Neurol. 2022 Oct 6. pii: 10.1007/s00415-022-11415.
     PubMed     Abstract available
     
     
     
144. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
     The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
     J Neurol. 2022;269:5319-5327.
     PubMed     Abstract available
     
     
     September 2022
145. MARGONI M, Pagani E, Preziosa P, Palombo M, et al
     In vivo quantification of brain soma and neurite density abnormalities in multiple sclerosis.
     J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11386.
     PubMed     Abstract available
     
     
     
146. PAGANI E, Storelli L, Pantano P, Petsas N, et al
     Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis.
     J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11387.
     PubMed     Abstract available
     
     
     
147. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
     Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
     J Neurol. 2022 Sep 22. pii: 10.1007/s00415-022-11385.
     PubMed    
     
     
     
148. FILSER M, Buchner A, Fink GR, Gold SM, et al
     The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.
     J Neurol. 2022 Sep 21. pii: 10.1007/s00415-022-11359.
     PubMed     Abstract available
     
     
     
149. CHAPPUIS M, Rousseau C, Bajeux E, Wiertlewski S, et al
     Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
     J Neurol. 2022 Sep 16. pii: 10.1007/s00415-022-11341.
     PubMed     Abstract available
     
     
     
150. NICOLAS P, Marion-Moffet H, Gossez M, Vukusic S, et al
     Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies.
     J Neurol. 2022 Sep 12. pii: 10.1007/s00415-022-11353.
     PubMed    
     
     
     
151. CAPASSO N, Palladino R, Cerbone V, Spiezia AL, et al
     Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
     J Neurol. 2022 Sep 1. pii: 10.1007/s00415-022-11350.
     PubMed     Abstract available
     
     
     August 2022
152. WOELFLE T, Pless S, Reyes O, Wiencierz A, et al
     Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
     J Neurol. 2022 Aug 30. pii: 10.1007/s00415-022-11306.
     PubMed     Abstract available
     
     
     
153. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
     The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.
     J Neurol. 2022 Aug 8. pii: 10.1007/s00415-022-11295.
     PubMed     Abstract available
     
     
     
154. KREFT KL, Robertson NP
     Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment.
     J Neurol. 2022 Aug 1. pii: 10.1007/s00415-022-11300.
     PubMed    
     
     
     July 2022
155. CAPUANO R, Altieri M, Conte M, Bisecco A, et al
     Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
     J Neurol. 2022 Jul 26. pii: 10.1007/s00415-022-11296.
     PubMed     Abstract available
     
     
     
156. MUNOZ-JURADO A, Escribano BM, Aguera E, Caballero-Villarraso J, et al
     SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.
     J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11237.
     PubMed     Abstract available
     
     
     
157. EID K, Torkildsen O, Aarseth J, Celius EG, et al
     Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy.
     J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11249.
     PubMed     Abstract available
     
     
     
158. ALCALA C, Cubas L, Carratala S, Gascon F, et al
     NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
     J Neurol. 2022;269:3495-3500.
     PubMed     Abstract available
     
     
     June 2022
159. CANNIZZARO M, Ferre L, Clarelli F, Giordano A, et al
     Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
     J Neurol. 2022 Jun 27. pii: 10.1007/s00415-022-11227.
     PubMed     Abstract available
     
     
     
160. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
     Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
     J Neurol. 2022 Jun 25. pii: 10.1007/s00415-022-11216.
     PubMed    
     
     
     
161. LEGUY S, Lefort M, Lescot L, Michaud A, et al
     COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.
     J Neurol. 2022 Jun 23. pii: 10.1007/s00415-022-11215.
     PubMed     Abstract available
     
     
     
162. SANDROFF BM, Motl RW, Roman CAF, Wylie GR, et al
     Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis.
     J Neurol. 2022 Jun 19. pii: 10.1007/s00415-022-11205.
     PubMed     Abstract available
     
     
     
163. DORCET G, Migne H, Biotti D, Bost C, et al
     Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.
     J Neurol. 2022 Jun 2. pii: 10.1007/s00415-022-11197.
     PubMed     Abstract available
     
     
     
164. ZIEMSSEN T, Lang M, Schmidt S, Albrecht H, et al
     Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
     J Neurol. 2022;269:3276-3285.
     PubMed     Abstract available
     
     
     
165. DI SABATINO E, Gaetani L, Sperandei S, Fiacca A, et al
     The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
     J Neurol. 2022;269:3129-3135.
     PubMed     Abstract available
     
     
     
166. MISCIOSCIA A, Puthenparampil M, Miante S, Pengo M, et al
     Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.
     J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11183.
     PubMed     Abstract available
     
     
     May 2022
167. HRASTELJ J, Robertson NP
     A role for the Epstein-Barr virus in multiple sclerosis aetiology?
     J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11177.
     PubMed    
     
     
     
168. GOLD R, Piani-Meier D, Kappos L, Bar-Or A, et al
     Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
     J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11166.
     PubMed     Abstract available
     
     
     
169. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
     Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
     J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11158.
     PubMed    
     
     
     
170. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
     Early use of high-efficacy diseasemodifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
     J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11193.
     PubMed     Abstract available
     
     
     
171. BATTAGLIA MA, Bezzini D, Cecchini I, Cordioli C, et al
     Patients with multiple sclerosis: a burden and cost of illness study.
     J Neurol. 2022 May 23. pii: 10.1007/s00415-022-11169.
     PubMed     Abstract available
     
     
     
172. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
     A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
     J Neurol. 2022 May 12. pii: 10.1007/s00415-022-11109.
     PubMed     Abstract available
     
     
     
173. HONE L, Jacobs BM, Marshall C, Giovannoni G, et al
     Age-specific effects of childhood body mass index on multiple sclerosis risk.
     J Neurol. 2022 May 9. pii: 10.1007/s00415-022-11161.
     PubMed     Abstract available
     
     
     
174. SPARASCI D, Gobbi C, Castelnovo A, Riccitelli GC, et al
     Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.
     J Neurol. 2022 May 4. pii: 10.1007/s00415-022-11143.
     PubMed     Abstract available
     
     
     
175. KIM H, Fraser S
     Neural correlates of dual-task walking in people with central neurological disorders: a systematic review.
     J Neurol. 2022;269:2378-2402.
     PubMed     Abstract available
     
     
     April 2022
176. HVID LG, Stenager E, Dalgas U
     Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.
     J Neurol. 2022 Apr 28. pii: 10.1007/s00415-022-11134.
     PubMed     Abstract available
     
     
     
177. EINSIEDLER M, Kremer L, Fleury M, Collongues N, et al
     Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
     J Neurol. 2022 Apr 17. pii: 10.1007/s00415-022-11124.
     PubMed     Abstract available
     
     
     
178. DUBBIOSO R, Bove M, Boccia D, D'Ambrosio V, et al
     Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.
     J Neurol. 2022 Apr 13. pii: 10.1007/s00415-022-11114.
     PubMed     Abstract available
     
     
     
179. ZHANG Y, Yin H, Zhang D, Xu Y, et al
     Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
     J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11118.
     PubMed     Abstract available
     
     
     
180. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
     The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
     J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11063.
     PubMed     Abstract available
     
     
     
181. STORELLI L, Pagani E, Meani A, Preziosa P, et al
     Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.
     J Neurol. 2022 Apr 10. pii: 10.1007/s00415-022-11104.
     PubMed     Abstract available
     
     
     
182. CAROLUS K, Fuchs TA, Bergsland N, Ramasamy D, et al
     Time course of lesion-induced atrophy in multiple sclerosis.
     J Neurol. 2022 Apr 8. pii: 10.1007/s00415-022-11094.
     PubMed     Abstract available
     
     
     
183. MOOG TM, McCreary M, Wilson A, Stanley T, et al
     Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease.
     J Neurol. 2022 Apr 5. pii: 10.1007/s00415-022-11089.
     PubMed     Abstract available
     
     
     
184. BUONOMO AR, Viceconte G, Calabrese M, De Luca G, et al
     Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
     J Neurol. 2022 Apr 4. pii: 10.1007/s00415-022-11066.
     PubMed    
     
     
     
185. VANDEBERGH M, Degryse N, Dubois B, Goris A, et al
     Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.
     J Neurol. 2022 Apr 2. pii: 10.1007/s00415-022-11072.
     PubMed     Abstract available
     
     
     
186. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
     The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
     J Neurol. 2022;269:1758-1763.
     PubMed     Abstract available
     
     
     
187. ROJAS JI, Pappolla A, Blaya P, Marrodan M, et al
     Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM.
     J Neurol. 2022;269:2073-2079.
     PubMed     Abstract available
     
     
     
188. ABBOUD H, Salazar-Camelo A, George N, Planchon SM, et al
     Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.
     J Neurol. 2022;269:1786-1801.
     PubMed     Abstract available
     
     
     March 2022
189. DEANA C, Bagatto D, Battezzi A, Pecori D, et al
     Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
     J Neurol. 2022 Mar 30. pii: 10.1007/s00415-022-11097.
     PubMed    
     
     
     
190. BISECCO A, Fornasiero A, Bianco A, Cortese A, et al
     Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
     J Neurol. 2022 Mar 27. pii: 10.1007/s00415-022-11083.
     PubMed    
     
     
     
191. WENZEL N, Wittayer M, Weber CE, Schirmer L, et al
     MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.
     J Neurol. 2022 Mar 25. pii: 10.1007/s00415-022-11082.
     PubMed     Abstract available
     
     
     
192. ALLMAN M, Tallantyre E, Robertson NP
     Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.
     J Neurol. 2022 Mar 14. pii: 10.1007/s00415-022-11053.
     PubMed    
     
     
     
193. MISTRI D, Cacciaguerra L, Storelli L, Meani A, et al
     The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.
     J Neurol. 2022 Mar 12. pii: 10.1007/s00415-022-11044.
     PubMed     Abstract available
     
     
     
194. MARIOTTINI A, Bertozzi A, Marchi L, Di Cristinzi M, et al
     Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
     J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11003.
     PubMed     Abstract available
     
     
     
195. ACHIRON A, Mandel M, Gurevich M, Dreyer-Alster S, et al
     Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
     J Neurol. 2022 Mar 2. pii: 10.1007/s00415-022-11030.
     PubMed     Abstract available
     
     
     
196. KANINIA S, Edey AJ, Maskell NA, Rice CM, et al
     Natalizumab-induced pneumonitis.
     J Neurol. 2022;269:1688-1690.
     PubMed    
     
     
     
197. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
     Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
     J Neurol. 2022;269:1663-1669.
     PubMed     Abstract available
     
     
     
198. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
     The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
     J Neurol. 2022 Mar 1. pii: 10.1007/s00415-022-11021.
     PubMed     Abstract available
     
     
     February 2022
199. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
     Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
     J Neurol. 2022 Feb 22. pii: 10.1007/s00415-022-11019.
     PubMed    
     
     
     
200. BERG-HANSEN P, Moen SM, Austeng A, Gonzales V, et al
     Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation.
     J Neurol. 2022 Feb 15. pii: 10.1007/s00415-022-10998.
     PubMed     Abstract available
     
     
     
201. RICCARDO BA, Giulio V, Massimiliano C, Giovanna L, et al
     Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
     J Neurol. 2022 Feb 14. pii: 10.1007/s00415-022-11009.
     PubMed     Abstract available
     
     
     
202. CHIARAVALLOTI ND, Costa SL, Moore NB, Costanza K, et al
     The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial.
     J Neurol. 2022 Feb 12. pii: 10.1007/s00415-022-10980.
     PubMed     Abstract available
     
     
     
203. ALCALA C, Quintanilla-Bordas C, Gascon F, Sempere AP, et al
     Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
     J Neurol. 2022 Feb 2. pii: 10.1007/s00415-022-10989.
     PubMed     Abstract available
     
     
     
204. BUKHARI W, Khalilidehkordi E, Mason DF, Barnett MH, et al
     NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.
     J Neurol. 2022;269:836-845.
     PubMed     Abstract available
     
     
     
205. LANDI D, Signori A, Cellerino M, Fenu G, et al
     What happens after fingolimod discontinuation? A multicentre real-life experience.
     J Neurol. 2022;269:796-804.
     PubMed     Abstract available
     
     
     January 2022
206. VIRGILIO E, Vecchio D, Crespi I, Puricelli C, et al
     Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.
     J Neurol. 2022 Jan 28. pii: 10.1007/s00415-021-10945.
     PubMed     Abstract available
     
     
     
207. PROSCHINGER S, Kuhwand P, Rademacher A, Walzik D, et al
     Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression.
     J Neurol. 2022 Jan 27. pii: 10.1007/s00415-021-10935.
     PubMed     Abstract available
     
     
     
208. PAPADOPOULOS D, Gklinos P, Psarros G, Drellia K, et al
     Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
     J Neurol. 2022 Jan 23. pii: 10.1007/s00415-021-10932.
     PubMed     Abstract available
     
     
     
209. BERGAMASCHI R, Mallucci G, Fusco S, Montomoli C, et al
     Disability and mortality in a cohort of MS patients: how the real-world scenario is changed.
     J Neurol. 2022 Jan 14. pii: 10.1007/s00415-021-10940.
     PubMed    
     
     
     
210. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
     Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
     J Neurol. 2022 Jan 10. pii: 10.1007/s00415-021-10958.
     PubMed     Abstract available
     
     
     
211. CRUZ RA, Varkey T, Flavia A, Samways APA, et al
     Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms.
     J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10915.
     PubMed     Abstract available
     
     
     
212. KORSEN M, Pfeuffer S, Rolfes L, Meuth SG, et al
     Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
     J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10956.
     PubMed     Abstract available
     
     
     
213. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
     Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.
     J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10951.
     PubMed     Abstract available
     
     
     
214. BIGAUT K, Kremer L, Fabacher T, Ahle G, et al
     Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
     J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10950.
     PubMed     Abstract available
     
     
     
215. THOMAS R, Wynford-Thomas R, Robertson NP
     Advances in the use of stem cell transplants in the treatment of multiple sclerosis.
     J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10927.
     PubMed    
     
     
     
216. ZRZAVY T, Wielandner A, Haider L, Bartsch S, et al
     FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols.
     J Neurol. 2022;269:461-467.
     PubMed     Abstract available
     
     
     
217. HELMCHEN C, Buttler GM, Markewitz R, Hummel K, et al
     Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2.
     J Neurol. 2022;269:49-54.
     PubMed    
     
     
     
218. DE LOTT LB, Bennett JL, Costello F
     The changing landscape of optic neuritis: a narrative review.
     J Neurol. 2022;269:111-124.
     PubMed     Abstract available
     
     
     November 2021
219. RIO J, Rovira A, Gasperini C, Tintore M, et al
     Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
     J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10906.
     PubMed    
     
     
     
220. SRIWASTAVA S, Chaudhary D, Srivastava S, Beard K, et al
     Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
     J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10910.
     PubMed     Abstract available
     
     
     October 2021
221. FUCHS TA, Schoonheim MM, Broeders TAA, Hulst HE, et al
     Functional network dynamics and decreased conscientiousness in multiple sclerosis.
     J Neurol. 2021 Oct 29. pii: 10.1007/s00415-021-10860.
     PubMed     Abstract available
     
     
     
222. WASHINGTON F, Langdon D
     Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
     J Neurol. 2021 Oct 21. pii: 10.1007/s00415-021-10850.
     PubMed     Abstract available
     
     
     
223. ALSCHULER KN, Whibley D, Kratz AL, Jensen MP, et al
     Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome.
     J Neurol. 2021 Oct 19. pii: 10.1007/s00415-021-10842.
     PubMed     Abstract available
     
     
     
224. BURT RK, Han X, Quigley K, Helenowski IB, et al
     Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
     J Neurol. 2021 Oct 11. pii: 10.1007/s00415-021-10820.
     PubMed     Abstract available
     
     
     
225. FILIPPI M, Danesi R, Derfuss T, Duddy M, et al
     Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
     J Neurol. 2021 Oct 9. pii: 10.1007/s00415-021-10836.
     PubMed     Abstract available
     
     
     
226. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
     Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
     J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
     PubMed     Abstract available
     
     
     
227. RIO J, Rovira A, Gasperini C, Tintore M, et al
     Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
     J Neurol. 2021 Oct 1. pii: 10.1007/s00415-021-10823.
     PubMed     Abstract available
     
     
     
228. JARIUS S, Wilken D, Haas J, Ruprecht K, et al
     Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
     J Neurol. 2021;268:3758-3765.
     PubMed     Abstract available
     
     
     September 2021
229. PUTHENPARAMPIL M, Perini P, Bergamaschi R, Capobianco M, et al
     Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors.
     J Neurol. 2021 Sep 27. pii: 10.1007/s00415-021-10782.
     PubMed     Abstract available
     
     
     
230. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
     Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
     J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
     PubMed     Abstract available
     
     
     
231. ANDERSEN MA, Buron MD, Magyari M
     Late-onset MS is associated with an increased rate of reaching disability milestones.
     J Neurol. 2021;268:3352-3360.
     PubMed     Abstract available
     
     
     August 2021
232. SUN J, Xie Y, Wang Q, Shen J, et al
     Genes associated with grey matter volume reduction in multiple sclerosis.
     J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
     PubMed     Abstract available
     
     
     
233. BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
     Identifying falls remotely in people with multiple sclerosis.
     J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
     PubMed     Abstract available
     
     
     
234. MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
     Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
     J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
     PubMed     Abstract available
     
     
     
235. ALVINO B, Arianna F, Assunta B, Antonio C, et al
     Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
     J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
     PubMed     Abstract available
     
     
     
236. PARDO G, Coates S, Okuda DT
     Outcome measures assisting treatment optimization in multiple sclerosis.
     J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
     PubMed     Abstract available
     
     
     
237. CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
     Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
     J Neurol. 2021;268:2895-2899.
     PubMed     Abstract available
     
     
     
238. CILINGIR V, Batur M
     First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
     J Neurol. 2021;268:2858-2865.
     PubMed     Abstract available
     
     
     July 2021
239. FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
     Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
     J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
     PubMed     Abstract available
     
     
     
240. RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
     Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
     J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
     PubMed     Abstract available
     
     
     
241. NIESSEN A, Schwarz B, Urban M, Kramer S, et al
     Aseptic meningitis after glatiramer acetate.
     J Neurol. 2021;268:2589-2590.
     PubMed    
     
     
     June 2021
242. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
     PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
     J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
     PubMed     Abstract available
     
     
     
243. SANKARI SE, Van Essche C, van Pesch V
     Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
     J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.
     PubMed    
     
     
     
244. KOGEL AK, Gold R, Schneider R
     CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
     J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.
     PubMed    
     
     
     
245. S G, S L, C Z, A N, et al
     Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
     J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
     PubMed     Abstract available
     
     
     
246. HANNINEN K, Viitala M, Atula S, Laakso SM, et al
     Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
     J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
     PubMed     Abstract available
     
     
     
247. HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
     First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
     J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.
     PubMed    
     
     
     May 2021
248. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
     Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
     J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
     PubMed     Abstract available
     
     
     
249. CHEN MH, Chiaravalloti ND, DeLuca J
     Neurological update: cognitive rehabilitation in multiple sclerosis.
     J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
     PubMed     Abstract available
     
     
     
250. ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
     Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
     J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
     PubMed     Abstract available
     
     
     
251. HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
     Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
     J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
     PubMed     Abstract available
     
     
     
252. TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
     Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
     J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
     PubMed     Abstract available
     
     
     
253. RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
     A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
     J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
     PubMed     Abstract available
     
     
     April 2021
254. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
     Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
     J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
     PubMed     Abstract available
     
     
     
255. COVEY TJ, Golan D, Doniger GM, Sergott R, et al
     Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
     J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
     PubMed     Abstract available
     
     
     
256. CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
     Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
     J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
     PubMed     Abstract available
     
     
     
257. NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
     Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
     J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
     PubMed     Abstract available
     
     
     March 2021
258. MATHEY G, Pische G, Soudant M, Pittion-Vouyovitch S, et al
     Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.
     J Neurol. 2021 Mar 31. pii: 10.1007/s00415-021-10501.
     PubMed     Abstract available
     
     
     
259. PINTER D, Kober SE, Fruhwirth V, Berger L, et al
     MRI correlates of cognitive improvement after home-based EEG neurofeedback training in patients with multiple sclerosis: a pilot study.
     J Neurol. 2021 Mar 30. pii: 10.1007/s00415-021-10530.
     PubMed     Abstract available
     
     
     
260. HJAERESEN S, Sejbaek T, Axelsson M, Vinslov-Jensen H, et al
     The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis.
     J Neurol. 2021 Mar 4. pii: 10.1007/s00415-021-10489.
     PubMed     Abstract available
     
     
     February 2021
261. BUCELLO S, Annovazzi P, Ragonese P, Altieri M, et al
     Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
     J Neurol. 2021 Feb 22. pii: 10.1007/s00415-021-10455.
     PubMed     Abstract available
     
     
     
262. WALZL D, Solomon AJ, Stone J
     Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap.
     J Neurol. 2021 Feb 21. pii: 10.1007/s00415-021-10436.
     PubMed     Abstract available
     
     
     
263. CAPONE F, Ferraro E, Motolese F, Di Lazzaro V, et al
     COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
     J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10446.
     PubMed    
     
     
     
264. FILIPPI M, Capra R, Centonze D, Gasperini C, et al
     Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus.
     J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10466.
     PubMed    
     
     
     
265. JAKIMOVSKI D, Benedict RHB, Weinstock-Guttman B, Ozel O, et al
     Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?
     J Neurol. 2021 Feb 15. pii: 10.1007/s00415-021-10437.
     PubMed     Abstract available
     
     
     
266. TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al
     The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI.
     J Neurol. 2021 Feb 1. pii: 10.1007/s00415-021-10400.
     PubMed     Abstract available
     
     
     
267. BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
     Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
     J Neurol. 2021;268:651-657.
     PubMed     Abstract available
     
     
     January 2021
268. LUCCHINI M, Prosperini L, Buscarinu MC, Centonze D, et al
     Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
     J Neurol. 2021 Jan 26. pii: 10.1007/s00415-021-10412.
     PubMed     Abstract available
     
     
     
269. HARES K, Kemp K, Loveless S, Rice CM, et al
     KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis.
     J Neurol. 2021 Jan 23. pii: 10.1007/s00415-020-10373.
     PubMed     Abstract available
     
     
     
270. BOREMALM M, Sundstrom P, Salzer J
     Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis.
     J Neurol. 2021 Jan 21. pii: 10.1007/s00415-021-10399.
     PubMed     Abstract available
     
     
     
271. CHISARI CG, Sgarlata E, Arena S, Toscano S, et al
     Rituximab for the treatment of multiple sclerosis: a review.
     J Neurol. 2021 Jan 8. pii: 10.1007/s00415-020-10362.
     PubMed     Abstract available
     
     
     
272. KEVER A, Buyukturkoglu K, Riley CS, De Jager PL, et al
     Social support is linked to mental health, quality of life, and motor function in multiple sclerosis.
     J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10330.
     PubMed     Abstract available
     
     
     
273. GELIBTER S, Pisa M, Croese T, Dalla Costa G, et al
     Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?
     J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10322.
     PubMed     Abstract available
     
     
     
274. ZHUO Z, Li Y, Duan Y, Cao G, et al
     Subtyping relapsing-remitting multiple sclerosis using structural MRI.
     J Neurol. 2021 Jan 2. pii: 10.1007/s00415-020-10376.
     PubMed     Abstract available
     
     
     
275. WOO MS, Steins D, Haussler V, Kohsar M, et al
     Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.
     J Neurol. 2021;268:5-7.
     PubMed    
     
     
     December 2020
276. NEMA E, Kalina A, Nikolai T, Vyhnalek M, et al
     Correction to: Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?
     J Neurol. 2020 Dec 30. pii: 10.1007/s00415-020-10294.
     PubMed    
     
     
     
277. NEUSS F, von Podewils F, Wang ZI, Susse M, et al
     Epileptic seizures in multiple sclerosis: prevalence, competing causes and diagnostic accuracy.
     J Neurol. 2020 Dec 15. pii: 10.1007/s00415-020-10346.
     PubMed     Abstract available
     
     
     November 2020
278. PREZIOSA P, Rocca MA, Nozzolillo A, Moiola L, et al
     COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
     J Neurol. 2020 Nov 20. pii: 10.1007/s00415-020-10309.
     PubMed    
     
     
     October 2020
279. SIMONSEN CS, Flemmen HO, Broch L, Brunborg C, et al
     The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression.
     J Neurol. 2020 Oct 22. pii: 10.1007/s00415-020-10279.
     PubMed     Abstract available
     
     
     
280. ZECCA C, Disanto G, Sacco R, MacLachlan S, et al
     Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study.
     J Neurol. 2020 Oct 21. pii: 10.1007/s00415-020-10170.
     PubMed     Abstract available
     
     
     
281. ARNETH B
     Contributions of T cells in multiple sclerosis: what do we currently know?
     J Neurol. 2020 Oct 20. pii: 10.1007/s00415-020-10275.
     PubMed     Abstract available
     
     
     
282. WILLIS MD, Robertson NP
     Multiple sclerosis: early indicators of disease and assessing future risk.
     J Neurol. 2020 Oct 8. pii: 10.1007/s00415-020-10239.
     PubMed    
     
     
     September 2020
283. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
     Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
     J Neurol. 2020 Sep 24. pii: 10.1007/s00415-020-10226.
     PubMed     Abstract available
     
     
     July 2020
284. CAPUANO R, Altieri M, Bisecco A, d'Ambrosio A, et al
     Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?
     J Neurol. 2020 Jul 28. pii: 10.1007/s00415-020-10099.
     PubMed     Abstract available
     
     
     June 2020
285. VAN FAALS NL, Dekker I, Balk LJ, Moraal B, et al
     Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance.
     J Neurol. 2020 Jun 20. pii: 10.1007/s00415-020-09991.
     PubMed     Abstract available
     
     
     
286. PATTI F, Zimatore GB, Brescia Morra V, Aguglia U, et al
     Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
     J Neurol. 2020;267:1812-1823.
     PubMed     Abstract available
     
     
     
287. CAROTENUTO A, Costabile T, De Lucia M, Moccia M, et al
     Predictors of Nabiximols (Sativex((R))) discontinuation over long-term follow-up: a real-life study.
     J Neurol. 2020;267:1737-1743.
     PubMed     Abstract available
     
     
     January 2020
288. FREEDMAN MS, Brod S, Singer BA, Cohen BA, et al
     Clinical and MRI efficacy of sc IFN beta-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
     J Neurol. 2020;267:64-75.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.